Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis.
Paclitaxel-induced peripheral neuropathy is a common reason for dose reduction or early cessation of therapy. Nab-paclitaxel was developed to provide additional clinical benefits and overcome the safety drawbacks of solvent-based paclitaxel. However, the incidence of peripheral neuropathy induced by nab-paclitaxel was reported higher than solvent-based paclitaxel but evidence remains inconsistent. Therefore, we conducted a meta-analysis to compare the incidence and severity of peripheral neuropathy between nab-paclitaxel and solvent-based paclitaxel mono-chemotherapy. In total, 24 articles were included in this meta-analysis. Results revealed the incidence of peripheral neuropathy induced by nab-paclitaxel was higher than solvent-based paclitaxel. The dosage and assessment method could influence the comparison of the incidence and severity of peripheral neuropathy between nab-paclitaxel and solvent-based paclitaxel. Current evidence suggests the incidence of peripheral neuropathy induced by nab-paclitaxel was higher than solvent-based paclitaxel among cancer patients received mono-chemotherapy. When received nab-paclitaxel, more attention should be paid to peripheral neuropathy.
['Guo|Xi|X|', 'Sun|Hong|H|', 'Dong|Jihong|J|', 'Feng|Yi|Y|', 'Li|Hong|H|', 'Zhuang|Rongyuan|R|', 'Wang|Peipei|P|', 'Cai|Weimin|W|', 'Zhou|Yuhong|Y|']
D000418:Albumins D000972:Antineoplastic Agents, Phytogenic D006801:Humans D015994:Incidence D009369:Neoplasms D017239:Paclitaxel D010523:Peripheral Nervous System Diseases D011379:Prognosis D012997:Solvents
Nab-paclitaxel Incidence Peripheral neuropathy Solvent-based paclitaxel Meta-analysis